Rüschoff J - Search Results

1

Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.

Gloeckner-Hofmann K, Guillén-Gómez E, Schmidtgen C, Porstmann R, Ziegler R, Stoss O, Casado FJ, Rüschoff J, Pastor-Anglada M. Gloeckner-Hofmann K, et al. Among authors: ruschoff j. Oncology. 2006;70(3):238-44. doi: 10.1159/000094541. Epub 2006 Jul 12. Oncology. 2006. PMID: 16837820

2

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.

Heinmöller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M, Rüschoff J. Heinmöller P, et al. Among authors: ruschoff j. Clin Cancer Res. 2003 Nov 1;9(14):5238-43. Clin Cancer Res. 2003. PMID: 14614004 Clinical Trial.

3

[Gene expression profile in hormone refractory prostate cancer].

Stoss O, Jost N, Czeloth K, Rüschoff J, Henkel T, Albers P. Stoss O, et al. Among authors: ruschoff j. Urologe A. 2007 Sep;46(9):1117-9. doi: 10.1007/s00120-007-1447-x. Urologe A. 2007. PMID: 17639295 German. No abstract available.

4

[Her-2/neu analysis--new data?].

Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J. Gaiser T, et al. Among authors: ruschoff j. Verh Dtsch Ges Pathol. 2006;90:107-13. Verh Dtsch Ges Pathol. 2006. PMID: 17867586 German.

5

ISH-based HER2 diagnostics.

Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2021 Nov;42(Suppl 1):62-68. doi: 10.1007/s00292-020-00878-6. Epub 2020 Dec 21. Pathologe. 2021. PMID: 33346874 Review. English.

6

[ErbB2 diagnostics in breast cancer--an update].

Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. Rüschoff J, et al. Pathologe. 2009 Mar;30(2):147-55. doi: 10.1007/s00292-009-1126-3. Pathologe. 2009. PMID: 19214513 German.

7

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH. Rüschoff J, et al. Pathologe. 2010 May;31(3):208-17. doi: 10.1007/s00292-010-1278-1. Pathologe. 2010. PMID: 20443098 German.

8

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J. Stoss OC, et al. Among authors: ruschoff j. Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25. Mod Pathol. 2015. PMID: 26403781 Free article. Clinical Trial.

9

[ISH-based HER2 diagnostics].

Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2020 Nov;41(6):606-613. doi: 10.1007/s00292-020-00841-5. Pathologe. 2020. PMID: 33001242 Review. German.

10

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.

Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J. Hofmann M, et al. Among authors: ruschoff j. J Clin Pathol. 2008 Jan;61(1):89-94. doi: 10.1136/jcp.2006.043562. Epub 2007 Apr 5. J Clin Pathol. 2008. PMID: 17412870 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

345 results

Search Page

Filters